Stereotaxis has announced the publication of a paper in the European Heart Journal highlighting the benefits of using robotic technology for the management of ventricular tachycardia storm in a COVID-19 patient. The publication concludes that catheter ablation “should be performed preferably with a remote navigation system in order to minimise the infectious risk of the staff of the electrophysiology laboratory”.
Giovanni Forleo and colleagues at Luigi Sacco Hospital at the University of Milan (Milan, Italy) presented the case of a 68 year old patient diagnosed with COVID-19 who was admitted to the emergency department with multiple episodes of sustained ventricular tachycardia and electrical storm. COVID-19 has been associated with cardiovascular manifestations including ventricular arrhythmias. The patient’s arrhythmia was treated using catheter cardiac ablation with Stereotaxis’ robotic magnetic navigation system.
The publication states: “We used a remote magnetic navigation system since it has been thought to be superior to manual navigation for VT ablation (due to better contact force and stability) and in order to minimise unnecessary exposure of the electrophysiology laboratory staff to a likely COVID-19 patient.”
The procedure was successful and the patient did not experience ventricular tachycardia recurrence. The patient also recovered from COVID-19.
“We are proud to advance robotics in interventional medicine for the benefit of patients and healthcare professionals,” said David Fischel, Stereotaxis Chairman and CEO. “We are particularly grateful of the pronounced benefit of our technology for the most complex procedures in critical patients, while preserving the safety of the medical staff.”